Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEEL-224 in Pediatric Refractory or Relapsed Solid Tumors
NCT06721689Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Apr 2030
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PEEL-224 in solid tumor, neuroblastoma, rhabdomyosarcoma (RMS). Started Mar 2025; status: recruiting.
02
Drugs
PEEL-224
03
Conditions
solid tumorneuroblastomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT06721689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721689.